Search results
Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...
GuruFocus.com via Yahoo Finance· 18 hours agoRevenue: Q1 2024 revenue was $2.2 million, up from $0.7 million in Q1 2023. Cash, Cash Equivalents, and Investments: Ended Q1 2024 with $36.7 million. BARDA Funding: Received ...
Q1 2024 Vaxart Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 8 hours agoSecond, we expect to initiate our COVID-19 Phase 2b trial, possibly as early as this quarter, once we are able to secure additional funding and gain regulatory alignment. We have been honored ...
Earnings call: Gritstone bio details progress in cancer vaccine trials By Investing.com
Investing.com· 3 days agoGritstone bio (GRTS) has unveiled promising preliminary data from its GRANITE personalized cancer...
BTIG lowers Spectral AI shares amid slow burn trial enrollment By Investing.com
Investing.com· 7 days agoSpectral AI reported quarterly revenue of $6.3 million, which fell short of BTIG's estimates of $7.0...
Spectral AI, Inc. (NASDAQ:MDAI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoSpectral AI, Inc. (NASDAQ:MDAI) Q1 2024 Earnings Call Transcript May 11, 2024 Spectral AI, Inc....
Earnings call: AVITA Medical confronts growth challenges in Q1 By Investing.com
Investing.com· 9 hours agoAVITA Medical, Inc. (RCEL) has reported its first-quarter financial results, revealing a commercial...
Spectral AI hails progress towards first sales and pre-FDA clinical trial
Proactive Investors· 7 days agoAt the end of March, cash stood at $10.2 million, up from $4.8 million at the end of December, which...
Earnings call: Vaxart posts progress in vaccine trials, Q1 financials By Investing.com
Investing.com· 1 day agoVaxart, Inc. (NASDAQ: NASDAQ:VXRT), a biotechnology company specializing in the development of oral...
OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
GuruFocus.com via Yahoo Finance· 7 days ago:OPK) has several promising pharmaceutical programs set to enter clinical trials, including a multi-specific oncology antibody and a vaccine licensed to Merck. The company has secured non-dilutive ...
Opko Health (OPK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 7 days agoOur collaboration with BARDA is moving forward and provides non-dilutive financing to develop multispecific antibodies against COVID. As work progresses...